

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Insmed (brensocatib)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Asthma + Lung UK	Board of Community Health Councils
European Lung Foundation	in Wales
NARA – The Breathing Charity	British National Formulary
 Pulmonary Hypertension Association 	Care Quality Commission
UK	Chest, Heart and Stroke Scotland
South Asian Health FoundationSpecialised Healthcare Alliance	 Department of Health, Social Services and Public Safety for Northern Ireland
Specialization in the same of	Healthcare Improvement Scotland
Healthcare professional groups	Medicines and Healthcare products
Association of Respiratory Nurse	Regulatory Agency
Specialists	 National Association of Primary Care
Association for Respiratory Technology	National Pharmacy Association
and Physiology	NHS Confederation
British Geriatrics Society	 NHS Wales Joint Commissioning
British Institute of Radiology	Committee
British Paediatric Respiratory Society	Northern Ireland Chest, Heart and
British Thoracic Society	Stroke Association
National Heart and Lung Institute	Scottish Medicines Consortium
 Neonatal and Paediatric Pharmacy Group 	Welsh Government
Primary Care Respiratory Society UK	Possible comparator companies
Royal College of General Practitioners	None
Royal College of Nursing	
Royal College of Paediatrics & Child	Relevant research groups
Health	Asthma, Allergy and Inflammation
Royal College of Pathologists	Research Charity
Royal College of Physicians	Breathing Matters
Royal College of Radiologists	British Association for Lung Research
Royal Pharmaceutical Society	BRONCH-UK
Royal Society of Medicine	Cochrane Airways Group

Provisional stakeholder list for the evaluation of brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Society and College of Radiographers	Genomics England
UK Clinical Pharmacy Association	MRC Clinical Trials Unit
	 National Institute for Health Research
<u>Others</u>	
 Department of Health and Social Care 	Associated Public Health groups
NHS England	Public Health Wales
	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,

Provisional stakeholder list for the evaluation of brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448 Issue date: July 2025





the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.